Carmine Therapeutics

Cambridge, United States

Carmine Therapeutics develops a novel type of gene therapy that utilizes extracellular vesicles produced in the laboratory.

Oct 2022

Series A

Biotechnology Health Care Pharmaceutical Therapeutics

Top Investors

Huagai Capital Simcere Pharma Cystic Fibrosis Foundation Esco Ventures EVX Ventures

Founder Contacts

30,000+ verified contacts

Get Instant Access

Emails, phones & LinkedIn profiles

Frequently Asked Questions about Carmine Therapeutics

Who are Carmine Therapeutics's investors?

Carmine Therapeutics's investors include Huagai Capital, Simcere Pharma, Cystic Fibrosis Foundation, Esco Ventures, EVX Ventures.

Where is Carmine Therapeutics headquartered?

Carmine Therapeutics is headquartered in Cambridge, United States.

What does Carmine Therapeutics do?

Carmine Therapeutics develops a novel type of gene therapy that utilizes extracellular vesicles produced in the laboratory.

What stage is Carmine Therapeutics at?

Carmine Therapeutics is at the Series A stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated October 13, 2022.

MLA

"Carmine Therapeutics — Funding & Investors." VCBacked, October 13, 2022, https://www.vcbacked.co/company/carmine-therapeutics. Accessed July 3, 2026.

APA

VCBacked. (2022). Carmine Therapeutics — Funding & Investors. Retrieved July 3, 2026, from https://www.vcbacked.co/company/carmine-therapeutics

Wikipedia (cite web)

{{cite web |title=Carmine Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/carmine-therapeutics |website=VCBacked |access-date=July 3, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated October 13, 2022.